InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Trading Halt 28 Apr 2023 6:22PM $0.100 $0.230 risen by 130%
- MND Trial Successfully Completes Second Patient Cohort 28 Apr 2023 8:34AM $0.099 $0.230 risen by 132.32%
- Canine Trial Update 21 Apr 2023 8:18AM $0.100 $0.230 risen by 130%
- Arrival of additional MPL tablets 17 Apr 2023 8:27AM $0.110 $0.230 risen by 109.09%
- PharmAust launches international CEO search 13 Apr 2023 8:22AM $0.099 $0.230 risen by 132.32%
- MND Trial Completes Enrolment of Cohort 2 30 Mar 2023 9:17AM $0.091 $0.230 risen by 152.75%
- Stable Patient in MND trial reaches 6-months on MPL 28 Mar 2023 9:21AM $0.084 $0.230 risen by 173.81%
- PharmAust Investor Webinar Presentation 16 Mar 2023 8:13AM $0.085 $0.230 risen by 170.59%
- AOG Energy Conference Presentation 15 Mar 2023 7:35PM $0.085 $0.230 risen by 170.59%
- Investor Webinar 14 Mar 2023 10:31AM $0.086 $0.230 risen by 167.44%
- Correction to Appendix 3Y 13 Mar 2023 5:17PM $0.086 $0.230 risen by 167.44%
- Change of Director's Interest Notice 13 Mar 2023 9:39AM $0.087 $0.230 risen by 164.37%
- Canine Cancer Trial Update 7 Mar 2023 8:19AM $0.086 $0.230 risen by 167.44%
- Interim analysis recommended in MND trial 2 Mar 2023 8:14AM $0.081 $0.230 risen by 183.95%
- European Patent relating to MPL Combinations in Cancer 28 Feb 2023 7:57AM $0.081 $0.230 risen by 185.71%
- Appendix 4D & Half Year Report 27 Feb 2023 4:10PM $0.081 $0.230 risen by 185.71%
- First Patient of Cohort 2 Dosed in MND Trial 20 Feb 2023 8:03AM $0.081 $0.230 risen by 183.95%
- PharmAust canine trial update 10 Feb 2023 9:45AM $0.083 $0.230 risen by 177.11%
- Appendix 4C and Quarterly Update 30 Jan 2023 3:46PM $0.085 $0.230 risen by 170.59%
- PharmAust Progresses to Elevated Doses in MND Patients 20 Jan 2023 8:22AM $0.087 $0.230 risen by 164.37%
- Change of Director's Interest Notice 10 Jan 2023 4:35PM $0.082 $0.230 risen by 180.49%
- MND Trial Successfully Completes First Patient Cohort 6 Jan 2023 9:09AM $0.064 $0.230 risen by 259.38%
- PharmAust Canine Trial Update clarification 20 Dec 2022 1:02PM $0.064 $0.230 risen by 259.38%
- PharmAust Canine Trial Update 20 Dec 2022 8:20AM $0.067 $0.230 risen by 243.28%
- PharmAust Receives R&D Tax Incentive Refund 12 Dec 2022 9:12AM $0.069 $0.230 risen by 233.33%

201 - 225 of 796 results

Page 9 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.